GSK (LON:GSK) Shares Break Below Fifty Day Moving Average – Time to Sell?

GSK plc (LON:GSK – Get Free Report) crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of GBX 1,851.56 and traded as low as GBX 1,821. GSK shares last traded at GBX 1,827, with a volume of 5,107,288 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on GSK shares. Jefferies Financial Group reissued a “buy” rating and set a GBX 2,500 price target on shares of GSK in a research note on Tuesday, October 20th. Royal Bank Of Canada started coverage on GSK in a report on Tuesday, September 8th. They issued a “sector perform” rating and a GBX 1,975 price target on the stock. Deutsche Bank reissued a “hold” rating and set a GBX 2,000 price target on shares of GSK in a research report on Tuesday, November 10th. Finally, Berenberg Bank restated a “buy” rating and set a GBX 2,200 target price on shares of GSK in a report on Tuesday, November 3rd. Three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of GBX 2,145.

Check Out Our Latest Stock Analysis on GSK

GSK Stock Performance

The stock has a 50 day simple moving average of GBX 1,853 and a 200 day simple moving average of GBX 1,951.50. The company has a current ratio of 0.86, a quick ratio of 0.73 and a debt-to-equity ratio of 126.38. The stock has a market cap of £73.86 billion, a P/E ratio of 17.24, a price-to-earnings-growth ratio of 1.24 and a beta of 0.28.

GSK (LON:GSK – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The company reported GBX 54.60 earnings per share (EPS) for the quarter. The firm had revenue of GBX 888.70 billion for the quarter. GSK had a net margin of 12.97% and a return on equity of 24.64%. On average, equities analysts expect that GSK plc will post 175.98 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Jonathan Symonds purchased 1,500 shares of GSK stock in a transaction dated Friday, September 18th. The shares were bought at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Also, insider Anne Beal purchased 637 shares of the business’s stock in a transaction dated Friday, September 18th. The shares were acquired at an average price of GBX 4,985 per share, for a total transaction of £31,754.45. Over the last quarter, insiders have purchased 2,151 shares of company stock valued at $6,021,921. 0.20% of the stock is owned by corporate insiders.

GSK Company Profile

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

Further Reading

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.